Hims & Hers Health, Inc.

Hims & Hers has transformed from a hair-loss and ED telehealth brand into a vertically-integrated direct-to-consumer healthcare platform — 2.5M+ subscribers, ~$83 ARPU, $2.35B revenue (+69% YoY), and GAAP profitability. The investment thesis now hinges almost entirely on one question: will peptides become the next growth engine?

After losing the compounded-GLP-1 revenue stream (Novo partnership March '26 + FDA enforcement) and with a SEC investigation overhang, management has pivoted to a broader peptide platform strategy anchored by a California peptide manufacturing facility (acquired Feb 2025). The July 2026 FDA Pharmacy Compounding Advisory Committee meeting will rule on whether peptides (BPC-157, thymosin, GHK-Cu, and others) enter the 503A bulk list — which would legitimize compounded wellness peptides at scale. RFK Jr./HHS has publicly signaled support. The core business remains strong (FY26 guide $2.7–$2.9B revenue, $300–$375M adj. EBITDA), but the stock at ~$28 is pricing in a worse outcome than the probability-weighted scenarios imply.

• [CATALYST]
  July 2026 FDA Advisory CommitteeThe FDA Pharmacy Compounding Advisory Committee meets to rule on whether peptides enter the 503A bulk substances list — a binary event for the stock.
• [PIVOT]
  The GLP-1 revenue stream disappearedThe oral GLP-1 pill was withdrawn in Feb '26 after the FDA deemed it an "unapproved copycat"; the March '26 Novo Nordisk settlement replaced compounded GLP-1 with a lower-margin branded partnership, forcing the peptide pivot.
• [POLICY]
  RFK Jr. / HHS tailwindRFK Jr. and HHS have publicly signaled support for expanding compounding access to wellness peptides, ahead of the July committee vote.
• [OVERHANG]
  Unresolved SEC investigationAn open SEC investigation sits alongside the FDA catalyst, with resolution timing uncertain.

The 503A pathway allows personalized compounding by pharmacies on individual prescriptions. If these peptides make the list, HIMS can legally compound and sell them through its telehealth platform at high gross margins versus the ~50% margin on branded partnership GLP-1s. Management has telegraphed that peptide wellness could be a $500M–$1B revenue category within 2–3 years. Conversely, if the committee rejects key peptides, the growth algorithm decelerates sharply and the stock re-rates lower on a core-business-only multiple.

Note: the report's narrative section for each scenario states slightly different returns (-38% / +24% / +101%) than the summary strip above, against the same $28.16 current price and the same $20/$40/$65 targets. Both figures are reproduced here exactly as published in the source material.

Base Case — $40 (+24% per source narrative): the FDA adds a subset of peptides to the 503A list — BPC-157, GHK-Cu, and thymosin alpha-1 legitimized, tesofensine and others deferred. HIMS ramps its peptide wellness offering toward $150M of peptide revenue by end of 2026 (~5% of revenue), the Novo partnership provides stable branded GLP-1 revenue, and FY26 lands mid-guide ($2.8B revenue, $340M EBITDA). Growth reaccelerates to ~25% in FY27 as the peptide platform scales and EBITDA margin expands to ~14%; the multiple holds at 3.0x EV/Revenue (~$40), aligned with the median analyst target, and the SEC investigation resolves with a modest settlement or no major findings. Probability estimate: ~45–50%.

At ~$28, HIMS has an expected value skewed to the upside driven by the July FDA peptide ruling. Using the report's probability-weighted scenarios (27.5% bear / 47.5% base / 25% bull), expected value computes to ~$41 — roughly 45% above the current price, with binary upside/downside asymmetry on the July catalyst itself. The thesis only works if you believe: (1) the core telehealth business can hold at 20%+ growth without compounded GLP-1, (2) the peptide 503A path has a reasonable chance of partial-to-full approval, and (3) HIMS's manufacturing vertical integration is a durable moat. Position sizing: 1–2% portfolio weight with an explicit stop-loss below $19 (below the bear case); consider protective puts through July for tail-risk hedging.